2017 Press Releases


Keyword Search
2018 | 2017 | 2016 | 2015
DateTitle 
12/14/17Tocagen Added to NASDAQ Biotechnology IndexPrinter Friendly Version
11/21/17Tocagen Announces Time Change for Presentation at Evercore ISI Biopharma Catalyst/Deep Dive ConferencePrinter Friendly Version
11/10/17Tocagen to Present at Two Investor Conferences in NovemberPrinter Friendly Version
11/09/17Tocagen to Present Updated Clinical and Preclinical Data at Three Scientific ConferencesPrinter Friendly Version
11/08/17Tocagen Reports Third Quarter 2017 Financial and Business ResultsPrinter Friendly Version
11/01/17Tocagen to Report Third Quarter 2017 Financial Results on Wednesday, November 8Printer Friendly Version
10/27/17Tocagen Presents Updated Durable Complete Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent High-Grade GliomaPrinter Friendly Version
10/26/17Tocagen to Accelerate Toca 511 & Toca FC Development into Pivotal Phase 3 TrialPrinter Friendly Version
10/17/17Tocagen to Present Updated Durable Response Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent Brain Cancer at the 2017 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsPrinter Friendly Version
08/09/17Tocagen Reports Second Quarter 2017 Financial and Business ResultsPrinter Friendly Version
08/02/17Tocagen to Report Second Quarter 2017 Financial Results on Wednesday, August 9Printer Friendly Version
07/24/17Tocagen Receives European Medicines Agency Priority Medicines (PRIME) Designation for Toca 511 in High Grade GliomaPrinter Friendly Version
06/19/17Complementary Preclinical Studies Published in Neuro-Oncology Demonstrate Immune Activation Mechanism of Tocagen's Toca 511 & Toca FCPrinter Friendly Version
05/23/17Tocagen Reports First Quarter 2017 Financial and Business ResultsPrinter Friendly Version
05/11/17Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual MeetingPrinter Friendly Version
04/19/17Tocagen Announces Closing of Initial Public Offering and Exercise of the Underwriters' OptionPrinter Friendly Version
04/13/17Tocagen Announces Pricing of Initial Public OfferingPrinter Friendly Version
03/16/17Tocagen to Present Anti-Tumor Immune Response Data at 2017 Keystone Symposia Printer Friendly Version
03/07/17Tocagen Appoints Mark Foletta as Executive Vice President and Chief Financial OfficerPrinter Friendly Version
02/23/17Tocagen Achieves Key Development Milestone for Lead Product: Phase 2 Randomized Trial in Patients with Recurrent Brain Cancer Fully Enrolled Top-Line Results Anticipated 1H 2018Printer Friendly Version
02/23/17Tocagen Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Toca 511 & Toca FC in Recurrent High Grade GliomaPrinter Friendly Version
01/17/17Tocagen to Present at Phacilitate Cell & Gene Therapy World 2017Printer Friendly Version
01/13/17Tocagen Expands Toca 5, Phase 2/3 Clinical Trial for Recurrent Brain Cancer, to South KoreaPrinter Friendly Version